Phosphodiesterase Type 5 Inhibitors Improve Endothelial Function and May Benefit Cardiovascular Conditions - 13/02/13
Requests for reprints should be addressed to Robert A. Kloner, MD, PhD, Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017-2395Abstract |
The effects of phosphodiesterase type 5 inhibitors on vasodilation mediated via nitric oxide–cyclic guanosine monophosphate are well described. Less is known about other mechanisms through which phosphodiesterase type 5 inhibitors benefit endothelial function, including normalization of serum biomarkers, increased levels of endothelial progenitor cells, ischemia–reperfusion protection mechanisms, and other actions specific to patients with diabetes. These various mechanisms are reviewed. Their impact on several cardiovascular diseases, including erectile dysfunction, pulmonary hypertension, heart failure, high-altitude pulmonary edema, Raynaud's phenomenon, coronary artery disease, diabetes, and atherosclerosis, is presented.
El texto completo de este artículo está disponible en PDF.Keywords : Atherosclerosis, Flow-mediated dilation, Heart failure, Hypertension, Nitric oxide, Pulmonary, Vasodilation
Esquema
| Funding: Please see conflict of interest text. |
|
| Conflict of Interest: Deborah M. Campoli-Richards, BSPharm, RPh, is an employee of Complete Healthcare Communications, Inc. which received financial support from Pfizer Inc in connection with the development of this manuscript. We would like to disclose that Dr Kloner has served on the speakers bureaus for Viagra (Pfizer) and Cialis (Lilly) in the past, but not for several years. Dr Jackson gives educational noncommercial talks sponsored by Pfizer, Bayer, and Lilly. Dr Stecher is an employee of Pfizer. Dr Schwartz has no disclosures. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
Vol 126 - N° 3
P. 192-199 - mars 2013 Regresar al número
Artículo precedente
- Atypical Chest Pain—It's Time to Be Rid of It
- Kenneth R. Bennett
- Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome
- Han-Mou Tsai
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?